The Business Times

Companies & Markets

The Business Times
Subscribe
Share on FacebookShare on TwitterView more
The Business Times
Create a free account with Business Times for seamless access across SPH Media products.
REGISTER
LOGIN

Companies & Markets

SUBSCRIBERS

Purchase of Salix adds gastrointestinal drugs to Valeant stable

Valeant will pay US$158 a share in cash for Salix in US$10.1 billion acquisition

Published Sun, Feb 22, 2015 · 09:50 PM
Share this article.

New York

VALEANT Pharmaceuticals International Inc agreed to buy Salix Pharmaceuticals Ltd for about US$10.1 billion, a person with knowledge of the matter said, to add gastrointestinal drugs to its stable of offerings.

Valeant will pay US$158 a share in cash for Salix, the person said, asking not to be identified because the company hasn't announced the deal. Salix shares rose US$7.11 to US$157.85 last Friday, almost completely eliminating any premium in the purchase price.

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Companies & Markets

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here